Probiotics as potential therapies in human gastrointestinal health

International Journal of Advances in Pharmaceutical Sciences

Volumn 1, Issue 2, 2010, Pages 96-110

  Murali Eswara, S ^a   Kavitha, B T V V ^a   Srikanth, J G ^a   Velmani, G ^a  

^a AM Reddy Memorial College of Pharmacy   (India)

Author keywords

Antibiotics induced ulcer; Bacterial translocation; Prebiotics

Indexed keywords

ANTIBIOTIC AGENT; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT;

ABDOMINAL SURGERY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; BACTERIAL METABOLISM; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM; BIOFILM; CELL ADHESION; CLOSTRIDIUM DIFFICILE INFECTION; COLON CANCER; COMPETITIVE INHIBITION; CROHN DISEASE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; ENTERITIS; ENTEROCOCCUS; ENTEROPATHY; ENZYME ACTIVITY; FUNGEMIA; GASTROINTESTINAL DISEASE; HEART FAILURE; HELICOBACTER INFECTION; HEPATIC ENCEPHALOPATHY; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; ILEITIS; IMMUNE RESPONSE; INFECTIOUS DIARRHEA; INTESTINE EPITHELIUM; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; LACTOSE INTOLERANCE; MUCOSAL IMMUNITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PANCREATITIS; PH; PHAGOCYTOSIS; POSTOPERATIVE COMPLICATION; RADIATION INJURY; REVIEW; ROTAVIRUS INFECTION; STAPHYLOCOCCUS INFECTION; TRAVELLER DIARRHEA; ULCERATIVE COLITIS;

EID: 79952032516     PISSN: None     EISSN: 09761055     Source Type: Journal    
DOI: 10.5138/ijaps.2010.0976.1055.01011     Document Type: Review

References (96)

1. Gibson GR, Roberfroid MB, Dietary Modulation of the Human Colonic Microbiota. Introducing the concept of prebiotics. J nutr 1995;125:1401-12.
2. Erika Isolauri, Yelda Sütas, Pasi Kankaanpää, Heikki Arvilommi and Seppo Salminen Probiotics: effects on immunity. American Journal of Clinical Nutrition, Vol. 73, No.2, 444S-450s, February 2001
3. Mailn M, Verronen P, Mykkanen H, et al. Increased Bacterial Urease activity in faeces in juvenile chronic arthritis: evidence of altread intestinal microflora. Br j rheumatol.1996;35:689-94.
4. Collins MD, et al. Reduces the risk of antibiotic, allergic and infectious diarrhoea. Am J Clin Nutr 1999;69(suppl):1052s-7s.
5. Fuller R, Probiotics in man and animals. J Appl Bacteriol -01-MAY-1989; 66(5): 365-78.
6. Sanders ME, Considerations for use of probiotic bacteria to modulate human health. J nutr 2000; 130(2s suppl):384s-390s.
7. Mauro Cassaro, Massimo Rugge, et al. Topographic Patterns of Intestinal Metaplasia and Gastric Cancer. The American Journal of Gastroenterology, Vol 95, No.6, 2000, pp 1431-8.
8. Glenn R. Gibson and Marcel B. Roberfroid Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics. J. Nutr. 1995 125: 1401-1412.
9. Wullt M, Hagslatt ML, Odenholt I:Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003, 35:365-367.
10. McFarland LV, Surawicz CM, Greenberg RN, et al.: A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994, 271:1913-1918.
11. Adams M R, Hall C J, Growth inhibition of food pathogens by lacticacid and acetic acid and their mixtures. International journal of food science & technology. Vol,23, issue 3, pages 287-292.
12. Christine V. Salmond, Rohan G. Kroll, and Ian R. Booth.The Effect of Food Preservatives on pH Homeostasis in Escherichia coli.J Gen Microbiol 1984 130: 2845-2850.
13. Salminen S, Bouley C, Boutron Ruault MC, Cummings JH, Franck A, Gibson GR,Isolauri E, Moreau MC, Roberfroid M, Rowland I. functional food science and gastrointestinal physiology and function. Br J Nutr, 1998,80(suppl 1):147-71.
14. Solauri E, Majamaa H, Arvola T, et al. lactobacillus casei GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology, 1993;105:1643-50.
15. Mossman TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-57.
16. Perdigon G, de Macias N, Alvarez S, Oliver G, de Ruiz Holgado AA. 1986. Effect on per orally administered lactobacilli on macrophage activity in mice. Infect. Immun. 53:404-10.
17. Perdigon G, de Macias N, Alvarez S, Oliver G, de Ruiz Holgado AA. 1988. Systemic augmentation of the immune response in mice by feeding fermented milks with Lactobacillus casei and Lactobacillus acidophilus. Immunology. 63:17-23.
18. Sütas Y, Soppi E, Korhonen H, et al. Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolysed with Lactobacillus GG-derived enzymes. J Allergy Clin Immunol 1996; 98:216-24.
19. Sütas Y, Hurme M, Isolauri E. Scand J Immunol. 1996 Jun;43(6):687-9.Down regulation of anti-CD3 antibody-induced IL-4 production by bovine caseins hydrolysed with Lactobacillus GG-derived enzymes.
20. Fedork N, Madsen KL, Probiotics and Prebiotics in gastrointestinal disorders. Curr opin gastroenterol 2004;20:149-55.
21. Isolauri E, Sutas Y, Kankaanpaa P, et al. Probiotics: effect on immunity. Am j clin nutr 2001;73(suppl):444S-50S.
22. Hu FB, Stampfer MJ, Manson JE, Rimm EB, Wolk A, Colditz GA, et al. Dietary intake of alpha-linolenic acid and risk of fatal ischemic heart disease among women.
23. McFarland LV, Surawicz CM, Greenberg RN, et al.: A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994, 271:1913-1918.
24. Castagliuolo I, Lamont JT, Nikulasson ST, et al. Saccharomyces boularidii protease inhibits clostridium difficile toxin A effects in the rat ileum. Infect immune 1996;64:5225-32.
25. Castagliuolo I, Riegler MF, Valenick L, et al. Saccharomyces boularidii protects inhibits the effects of clostridium difficille toxin a and b in human colonic mucosa. Infect immune 1999;67:302-07.
26. Probiotics.Availableon http://www.probiotics.com/html/background/scientificsummary.html.accessed on 08/12/2004.
27. Lactobacillus acidophilus. Danone world newsletter 1997:13(online) available on http://www.danonevitapole.com assessed on 08/12/2004.
28. Dunne C, Shanhan F, Biotherapeutic agents in the treatment of gasterointestinal disorders. Current treatment options in infectious disease 2003; 5:183-88.
29. Blehaut H, Massot J, Elmer GW, et al. Disposition kinetics of saccharomyces boulardii in man and rat. Biopharm drug dispos 1989;104:353-64.
30. McFarland LV, Surawicz CM, Greenberg RN, et al.: A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994, 271:1913-1918.
31. Brady LJ, Gallaher DD, Busta FF (February 2000). The role of probiotic cultures in the prevention of colon cancer. J. Nutr. 130 (2S Suppl): 410S-414S.
32. Rolfe, R. D. The Role of Probiotic Cultures in the Control of Gastrointestinal Health. Journal of Nutrition. 2000;130:396S-402S.)
33. Colum Dunne, Liam O'Mahony, Lisa Murphy, Gerardine Thornton, Darrin Morrissey, Sile O'Halloran, Maria Feeney, Sarah Flynn, Gerald Fitzgerald, Charles Daly, Barry Kiely, Gerald C O'Sullivan, Fergus Shanahan and J Kevin Collins. In vitro selection criteria for probiotic bacteria of human origin: Correlation with in vivo findings. American Journal of Clinical Nutrition, Vol. 73, No. 2, 386S-392s, February 2001.
34. Hamilton-Miller JM: The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 2003, 22:360-366.
35. Ushiyama A, Tanaka K, Aiba Y, et al.:Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection. J Gastroenterol Hepatol 2003, 18:986-991.
36. Cruchet S, Obregon MC, Salazar G, et al.: Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children. Nutrition 2003, 19:716-721.
37. Mukai T, Asasaka T, Sato E, et al.: Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 2002, 32:105-110.
38. McNaught CE, Woodcock NP, MacFie J, et al.: A prospective randomised study of the probiotic Lactobacillus plantarum 299V on indices of gut barrier function in elective surgical patients. Gut 2002, 51:827-831.
39. Sen S, Mullan MM, Parker TJ, et al.: Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002, 47:2615-2620.
40. Gionchetti P, Amadini C, Rizzello F, et al.: Probiotics for the treatment of postoperative complications following intestinal surgery. Best Pract Res Clin Gastroenterol 2003, 17:821-831.
41. Rayes N, Seehofer D, Muller AR, et al.: [Influence of probiotics and fibre on the incidence of bacterial infections following major abdominal surgery-results of a prospective trial]. Z Gastroenterol 2002, 40:869-876.
42. Gary W. Elmer, PhD; Christina M. Surawicz, MD; Lynne V. McFarland, PhD, A Neglected Modality for the Treatment and Prevention of Selected Intestinal and Vaginal Infections.JAMA. 1996;275(11):870-876.
43. Akyol S, Mas MR, Comert B, et al.: The effect of antibiotic and probiotic combination therapy on secondary pancreatic infections and oxidative stress parameters in experimental acute necrotizing pancreatitis. Pancreas 2003, 26:363-367.
44. Guandalini S, Pensabene L, Zikri MA, et al.:Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr 2000, 30:54-60.
45. Surawicz CM: Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Pract Res Clin Gastroenterol 2003, 17:775-783.
46. Kelleher SL, Casas I, Carbajal N, et al.: Supplementation of infant formula with the probiotic Lactobacillus reuteri and zinc: impact on enteric infection and nutrition in infant rhesus monkeys. J Pediatr Gastroenterol Nutr 2002, 35:162-168.
47. McFarland LV, Surawicz CM, Greenberg RN, et al.: A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994, 271:1913-1918.
48. Isolauri E: Probiotics for infectious diarrhoea. Gut 2003, 52:436-437.
49. Huang JS, Bousvaros A, Lee JW, et al.: Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002, 47:2625-2634.
50. Sambol SP, Merrigan MM, Tang JK, et al.: Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 2002, 186:1781-1789.
51. Cremonini F, Di Caro S, Nista EC, et al.: Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002, 16:1461-1467.
52. D'Souza AL, Rajkumar C, Cooke J, et al.: Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002, 324:1361.
53. Ahuja MC, Khamar B: Antibiotic associated diarrhoea: a controlled study comparing plain antibiotic with those containing protected lactobacilli. J Indian Med Assoc 2002, 100:334-335.
54. Sullivan A, Barkholt L, Nord CE:Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine. J Antimicrob Chemother 2003, 52:308-311.
55. Payne S, Gibson G, Wynne A, et al.:In vitro studies on colonization resistance of the human gut microbiota to Candida albicans and the effects of tetracycline and Lactobacillus plantarum LPK. Curr Issues Intest Microbiol 2003, 4:1-8.
56. Kim HJ, Camilleri M, McKinzie S, et al.: A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17:895-904.
57. Costa-Ribeiro H, Ribeiro TC, Mattos AP, et al.: Limitations of probiotic therapy in acute, severe dehydrating diarrhea. J Pediatr Gastroenterol Nutr 2003, 36:112-115.
58. Brigidi P, Vitali B, Swennen E, et al.: Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001, 152:735-741.
59. Femia AP, Luceri C, Dolara P, et al.: Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. Carcinogenesis 2002, 23:1953-1960.
60. Sen S, Mullan MM, Parker TJ, et al.: Effects of Lactobacillus plantarum 299v on symptoms and colonic fermentation in irritable bowel syndrome (IBS). Gut 2001, 48(suppl 1):A57.
61. O'Sullivan MA, O'Morain CA: Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000, 32:294-301.
62. Nobaek S, Johansson ML, Molin G, et al.: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000, 95:1231-1238.
63. Niedzielin K, Kordecki H, Kosik R: New possibility in the treatment of irritable bowel syndrome: probiotics as a modification of the microflora of the colon. Gastroenterology 1998, 114:A402.
64. Bauer TM, Fernandez J, Navasa M, et al.: Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. J Hepatol 2002, 36:501-506.
65. Tamboli CP, Caucheteux C, Cortot A, et al.: Probiotics in inflammatory bowel disease: a critical review. Best Pract Res Clin Gastroenterol 2003, 17:805-820.
66. Hart AL, Stagg AJ, Kamm MA: Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2003, 36:111-119.
67. Gionchetti P, Amadini C, Rizzello F, et al.: Probiotics-role in inflammatory bowel disease. Dig Liver Dis 2002, 34(suppl 2):S58-S62.
68. Bamba T, Kanauchi O, Andoh A, et al.: A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol 2002, 17:818-824.
69. Kanauchi O, Serizawa I, Araki Y, et al.: Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol 2003, 38:134-141.
70. Ishikawa H, Akedo I, Umesaki Y, et al.: Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003, 22:56-63.
71. Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001;73:430S-6S.
72. Gan BS, Kim J, Reid G, et al.:Lactobacillus fermentum RC-14 inhibits Staphylococcus aureus infection of surgical implants in rats. J Infect Dis 2002, 185:1369-1372.
73. Kecskes G, Belagyi T, Olah A: [Early jejunal nutrition with combined pre-and probiotics in acute pancreatitis-prospective, randomized, double-blind investigations]. Magy Seb 2003, 56:3-8.
74. Mangiante G, Colucci G, Canepari P, et al.:Lactobacillus plantarum reduces infection of pancreatic necrosis in experimental acute pancreatitis. Dig Surg 2001, 18:47-50.
75. Delia P, Sansotta G, Donato V, et al.: Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol 2002, 97:2150-2152.
76. Li Z, Yang S, Lin H, et al.: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37:343-350.
77. Solga SF: Probiotics can treat hepatic encephalopathy. Med Hypotheses 2003, 61:307-313.
78. Borody TJ, Warren EF, Leis S, et al.: Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003, 37:42-47.
79. Seksik P, Rigottier-Gois L, Gramet G, et al.: Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003, 52:237-242.
80. Guandalini S: Use of Lactobacillus-GG in paediatric Crohn's disease. Dig Liver Dis 2002, 34(suppl 2):S63-S65.
81. Gionchetti P, Rizzello F, Venturi A, et al.: Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999, 13:713-718.
82. Gionchetti P, Rizzello F, Helwig U, et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003, 124:1202-1209.
83. Cremonini F, Di Caro S, Covino M, et al.: Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002, 97:2744-2749.
84. Rafter J: Probiotics and colon cancer. Best Pract Res Clin Gastroenterol 2003, 17:849-859.
85. Rafter J: Lactic acid bacteria and cancer: mechanistic perspective. Br J Nutr 2002, 88(suppl 1):S89-S94.
86. Brady LJ, Gallaher DD, Busta FF (February 2000). The role of probiotic cultures in the prevention of colon cancer. J. Nutr. 130 (2S Suppl): 410S-414S.
87. Obermeier F, Dunger N, Strauch UG, et al.: Contrasting activity of cytosin-guanosin dinucleotide oligonucleotides in mice with experimental colitis. Clin Exp Immunol 2003, 134:217-224.
88. Kalliomaki M, Salminen S, Poussa T, et al.: Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003, 361:1869-1871.
89. Kirjavainen PV, Salminen SJ, Isolauri E: Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr 2003, 36:223-227.
90. Saavedra J, Probiotics and infectious diarrhea.Am J Gastroenterol 2000;95(Suppl):S8-S18
91. McCarthy M, Breaking up the bacterial happy home.Lancet 2001;23:357(9373):2032-2033.
92. Kuisma J, Mentula S, Jarvinen H, et al.: Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003, 17:509-515.
93. Borriello SP, Hammes WP, Holzapfel W, et al.: Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003, 36:775-780.
94. Isolauri E, Kirjavainen PV, Salminen S: Probiotics: a role in the treatment of intestinal infection and inflammation? Gut 2002, 50(suppl 3):III54-III59.
95. Riquelme AJ, Calvo MA, Guzman AM, et al.:Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003, 36:41-43.
96. Collins MD, et al. Reduces the risk of antibiotic, allergic and infectious diarrhoea. Am J Clin Nutr 1999; 69(suppl):1052s-7s. 153-166.